All In Biotech

NDA 020310 · Kramer

Nizoral Anti-Dandruff

Ketoconazole · Topical · Azole Antifungal

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1997

Oct 10, 1997

Approved uses

1

Original approval plus efficacy supplements

Registered trials

211

26 Phase 3, 4 recruiting

FAERS reports

17,634

9,513 serious, 1,123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 20, 2026.

Uses controls flaking, scaling and itching associated with dandruff

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NIZORAL ANTI-DANDRUFF · KETOCONAZOLE 1% · SHAMPOO, TOPICAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketoconazole" as an intervention, any sponsor and status, largest first.

All 211 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,779
  • off label use1,268
  • pruritus1,020
  • fatigue1,005
  • nausea897
  • rash874
  • diarrhoea838
  • headache768
  • pain753
  • psoriasis663
  • dyspnoea653
  • dizziness632

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004121
2005131
2006139
2007132
2008137
2009265
2010171
2011321
2012389
2013362
2014324
2015923
2016913
2017941
20181,195
20191,367
20201,276
20211,193
20221,206
20231,804
20241,385
20251,601
20261,338

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 817 on PubMed

Sponsor: Kramer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.